The Latest Research Results Of GLP

 

GLP

1.General Specification(in stock)
(1)API(Pure powder)
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-1-188
GLP-1 (7-37) CAS 106612-94-6
Molecular formula: C151H228N40O47
HS code: N/A
Molecular weight: 3355.67
EINECS number: N/A
Manufacturer: BLOOM TECH Wuxi Factory
Analysis: HPLC, LC-MS, HNMR
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Technology support: R&D Dept.-4

We provide GLP, please refer to the following website for detailed specifications and product information.

Product: https://www.bloomtechz.com/synthetic-chemical/api-researching-only/glp-1-7-37.html

On June 1, 2026, Hanmi Pharm. Co, Ltd. announced that it had reached a licensing agreement with Eli Lilly and Company, authorizing Eli Lilly to develop, produce, and commercialize the biopharmaceutical candidate molecule sonefpeglutide (LAPSGLP-2 analog) for Hanmi Pharm.

Sonefpeglutide is a new candidate drug that integrates the proprietary long-acting platform technology LAPSCOVERY from Korean and American pharmaceuticals. Previously, Hanmei Pharmaceutical had already applied LAPSCOVERY! The platform's biologics have obtained FDA approval for marketing in the United States; Currently, five global clinical trials using this platform are underway.

 

Hanmei Pharmaceutical has long focused on the biological function research of glucagon like peptide-2 (GLP-2), including promoting intestinal growth, reducing inflammation, protecting and regenerating intestinal mucosa, and has verified related effects through multiple non clinical studies. Hanmei Pharmaceutical has demonstrated the therapeutic potential of LAPSGLP-2 in multiple indications at multiple international academic conferences. At present, sonefpeglutide is in the global phase II clinical trial phase for short bowel syndrome (SBS).

According to the agreement, Hanmei Pharmaceutical will continue to complete the ongoing SBS Global Phase II trial: Li, while Lai will explore other clinical trial possibilities for sonefpeglutide based on existing non clinical and clinical data. According to the terms of the agreement, Hanmei Pharmaceuticals will receive a down payment of $75 million and be eligible for up to $1.185 billion in milestone payments based on clinical development, regulatory approvals, and commercialization progress. In addition, they will receive tiered royalty payments from post market sales of the product.

On May 28, 2026, GlaxoSmithKline (LSE/NYSE: GSK) released positive key data for its antisense oligonucleotide (AS0) drug bepirovesen for the treatment of chronic hepatitis B (CHB) today. The results of two Phase III clinical trials, B-Wel11INCT056308071 and B-We 2 [NCT05630820], will be published simultaneously in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL).

 

B-Wel1 and B-Wel1 2 are global multicenter, randomized double-blind controlled trials conducted in 29 countries worldwide. The experiment aims to evaluate the efficacy of bepirovesen in the treatment of chronic hepatitis B with nucleoside (NA) analogues and baseline surface antigen (HBsAg)<3000 J/m! The efficacy, safety, pharmacokinetic characteristics, and persistence of functional cure in the subjects. Primary endpoint assessment: Baseline surface antigen (HBSAg)<3000 U/m! The proportion of patients achieving functional cure among subjects was evaluated as a key secondary endpoint for subjects with baseline surface antigen (HBsAg)<1000 U/ml.

 

Functional cure is defined as the failure to detect hepatitis B DNA and hepatitis B surface antigen (HBSAg) in blood at least 24 weeks after stopping all treatment, indicating that the immune system can control infection without further medication.

Bepirovesen is a research-oriented antisense oligonucleotide (ASO) that can recognize and inhibit the production of genetic material (i.e. RNA) of the hepatitis B virus that causes chronic infections, potentially enabling the human immune system to regain control. Bepirovirsen can reduce the production of HBV related RNA and viral protein, reduce the level of hepatitis B surface antigen (HBSAg) in the blood, and stimulate the immune system to improve the chances of persistent response.

On June 1, 2026, Hisilicon Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Hisilicon Pharmaceutical Technology (Lhasa) Co., Ltd., signed an Authorization and R&D Cooperation Agreement with Liliv and Companv from the United States on May 29. The two parties will carry out strategic cooperation in the research and development of innovative drugs in multiple disease fields.

 

According to the agreement, Hisilicon will rely on a mature small molecule innovation technology platform and efficient new drug development capabilities to be responsible for the discovery and early research and development of up to five target innovative drug projects selected by Eli Lilly. Lilly will obtain the global exclusive rights of relevant projects or the global exclusive rights except for Chinese Mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan, China, while Hispec reserves the exclusive rights of some projects in Chinese Mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan, China, China.

According to the agreement, Hisilicon has the right to receive up to $87 million in down payments and recent payments, up to $2.967 billion in subsequent milestone payments, and is entitled to receive tiered sales commissions based on future net sales of the product.
This cooperation is the first authorization and R&D collaboration between Hisilicon and Eli Lilly, and both parties will leverage their respective advantages in innovative drug development to jointly accelerate the global promotion of innovative drugs.